menu
    • menu
    [{"orgOrder":0,"company":"Pureos Bioventures","sponsor":"Engimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"T-cell Receptor Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Pureos Bioventures","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Extended-release Capsule","sponsorNew":"Pureos Bioventures \/ Pureos Bioventures","highestDevelopmentStatusID":"2","companyTruncated":"Pureos Bioventures \/ Pureos Bioventures"},{"orgOrder":0,"company":"Pureos Bioventures","sponsor":"PulseSight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PST-809","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Pureos Bioventures","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Pureos Bioventures \/ Pureos Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"Pureos Bioventures \/ Pureos Bioventures"},{"orgOrder":0,"company":"Pureos Bioventures","sponsor":"PulseSight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"PST-611","moa":"Transferrin gene","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Pureos Bioventures","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pureos Bioventures \/ Pureos BioVentures","highestDevelopmentStatusID":"5","companyTruncated":"Pureos Bioventures \/ Pureos BioVentures"}]

    Find Clinical Drug Pipeline Developments & Deals by Pureos Bioventures

    Menu

    Pureos Bioventures

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pureos Bioventures

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pureos Bioventures

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PST-611

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Recipient : PulseSight Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            PulseSight Announces First Close of Series A to Fund Clinical Development of PST-611

                            Details : The company intends to use the net proceeds to fund clinical development of PST-611, a first in class non-viral vectorized therapy, in dry age-related macular degeneration (AMD).

                            Product Name : PST-611

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 13, 2025

                            Lead Product(s) : PST-611

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Recipient : PulseSight Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pureos Bioventures

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pureos Bioventures

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PST-809

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : PulseSight Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PulseSight Launches to Advance Non-Viral Gene Therapies for Severe Retinal Diseases

                            Details : PST-809, is a potential first-in-class therapy for wet age-related macular degeneration that comprises a dual-gene plasmid encoding for anti-VEGF, aflibercept, together with decorin.

                            Product Name : PST-809

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 27, 2024

                            Lead Product(s) : PST-809

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : PulseSight Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pureos Bioventures

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pureos Bioventures

                            Switzerland arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-cell Receptor Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Engimmune Therapeutics

                            Deal Size : $16.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Engimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-cell Receptor Therapeutics

                            Details : Proceeds from the financing will be used to further build Engimmune’s pipeline having T-cell receptor based therapies, expand the research team in Switzerland, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 03, 2022

                            Lead Product(s) : T-cell Receptor Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Engimmune Therapeutics

                            Deal Size : $16.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth